Skip to main content
. Author manuscript; available in PMC: 2016 Mar 13.
Published in final edited form as: ACS Infect Dis. 2015 Jan 21;1(3):140–148. doi: 10.1021/id5000458

Table 1.

Ability of Selected ML283 Analogues To Inhibit DENV Helicase-Catalyzed ATP Hydrolysis and RNA Unwinding

graphic file with name nihms689963u2.jpg
compd (CID)a R DENV ATPase IC50b (μM) DENV RNA- helicase IC50c (μM) HCV ATPase IC50d (μM) HCV DNA- helicase IC50e (μM) HCV RNA-helicase IC50f (μM)
1 (49849280) H 5.3 ± 1.2 ndg     69 ± 6  11 ± 1.5   8.5 ± 2
2 (49849300) 4-NH2 2.8 ± 0.6 7.6 ± 1.6     58 ± 10  10 ± 2.4   7.0 ± 1*
3 (49849294) 4-F 3.0 ± 0.4 6.6 ± 0.9     32 ± 7  5.2 ± 0.6   4.2 ± 2*
4 (49849282) 4-OCH3 3.0 ± 0.5 nd   115 ± 14  10 ± 2.6   nd
5 (49849290) 4-CO2CH3 0.4 ± 0.1 7.9 ± 2.5 >200 9.7 ± 4.6   nd
6 (49849302) 4-Cl 1.4 ± 0.2 5.6 ± 1.2     53 ± 4 3.4 ± 0.3   3.3 ± 1
7 (49849286) 4-CH3 1.1 ± 0.2 4.3 ± 1.9     61 ± 1 3.3 ± 0.3   3.9 ± 1
8 (49849276) 4-CF3 1.2 ± 0.2 5.2 ± 0.6   111 ± 60 1.8 ± 0.4   2.8 ± 2
9 (49849299) 4-t-Bu 4.0 ± 0.5 10 ± 3.4 >200 8.2 ± 1   8.8 ± 3*
10 (49849284) 4-N(CH3)2 3.4 ± 0.3 nd >200  11 ± 6.7   8.6 ± 2
11 (50930740) 4-Br 1.1 ± 0.1 5.0 ± 1.2     21 ± 6 5.2 ± 4   3.8 ± 0.4*
12 (46839370) 4-NHFmoc 1.3 ± 0.3 3.5 ± 1.7     39 ± 31 5.4 ± 1   2.8 ± 1
13 (50930730) 3-Cl 4.0 ± 0.8 5.1 ± 0.9     24 ± 5 2.6 ± 1   5.9 ± 2
14 (50930737) 3,4-di-Cl 2.7 ± 0.2 3.6 ± 0.9     53 ± 3 3.7 ± 1   3.9 ± 2*
15 (50930748) 2-CF3 5.4 ± 0.8 nd     71 ± 23  14 ± 1 22.8 ± 5
16 (50930755) 3-CF3 9.7 ± 3.1 nd >200  20 ± 12 22.4 ± 8
17 (50930745) 2-F,6-CF3 5.3 ± 6.8 nd     93 ± 16  17 ± 6 32.5 ± 7
18 (50930751) 2-F,3-CF3 4.3 ± 0.3 nd     42 ± 14 9.2 ± 3 11.9 ± 4*
19 (50930743) 3-F,4-CF3 3.5 ± 1.1 nd     55 ± 42  17 ± 7   5.4 ± 2
20 (50930749) 3,5-di-CF3  63 ± 20 7.7 ± 1.8 >200  22 ± 4 14.2 ± 2*
21 (50930741) 2-F,5-CF3 3.8 ± 0.2 5.4 ± 1.3     16 ± 2 6.4 ± 2   7.5 ± 2
22 (50930733) 3-F,6-CF3 7.2 ± 0.8 nd     65 ± 10  19 ± 15   nd
23 (50930732) 3-F,5-CF3  11 ± 5.7 nd >200  28 ± 7   9.8 ± 3
a

PubChem40 compound identification number (CID).

b

Half-maximal inhibitory concentration observed in assays monitoring DENV NS3h-catalyzed ATP hydrolysis.

c

Half-maximal inhibitory concentration observed in assays monitoring DENV NS3h RNA unwinding.

d

Half-maximal inhibitory concentration observed in assays monitoring HCV NS3h-catalyzed ATP hydrolysis.

e

Half-maximal inhibitory concentration in assays monitoring HCV NS3h DNA unwinding. Data from Li et al.36

f

Half-maximal inhibitory concentration in assays monitoring HCV NS3h RNA unwinding. Values marked with asterisks (*) were published previously in Ndjomou et al.12

g

nd, not determined.